OXT and post-traumatic stress disorder: MDMA-assisted therapy, recently validated in two Phase 3 trials, also significantly reduced depressive symptoms in PTSD patients, suggesting that its serotonin- and oxytocin-mediated mechanisms may address both conditions simultaneously [86].